MedPath

Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa

Early Phase 1
Not yet recruiting
Conditions
Retinitis Pigmentosa
Interventions
Device: blue light-absorbing sunglasses
Registration Number
NCT02465749
Lead Sponsor
Sun Yat-sen University
Brief Summary

The purpose of this study is to investigate the role of continuous oxygen therapy combined with blue light deprivation in prevention and control of retinitis pigmentosa, in order to find a new strategy of treatment for retinitis pigmentosa.

Detailed Description

Retinitis pigmentosa (RP) is one of of the major causes of blindness in ocular diseases.Up to now, the etiology of RP remained unclear, and there are no effective therapeutic methods. Several studies had showed that the retina of RP may be anoxic, and oxygen therapy, such as hyperbaric oxygen (hyperbaric oxygen, HBO) treatment, had shown a definite effect on RP. The investigators' previous researches also found that the retinal vessel oxygen saturation in patients with RP who were older than 40 years were significantly lower than normal controls, suggesting that oxygen may play an important role in the development of RP. Besides, many studies have revealed that blue light could damage retina pigment epithelium cells and photoreceptor cell specially. Therefore, investigators will combine continuous oxygen therapy and blue light deprivation therapy in the treatment for RP in this study, in order to find a new strategy of treatment for RP.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
404
Inclusion Criteria
  1. Severe patients with RP who meet the following criteria: (1) the EDTRS visual acuity of the good eye < 0.3 (low vision);(2) the radius of central visual field< 10 °(low vision)
  2. Age range from 18 to 60 years old, sex unlimited
  3. Able to adhere to treatment for more than 12 months
  4. Willing to participate in this trial, and sign the informed consent
Exclusion Criteria
  1. Serious opacity of cornea, lens or vitreous body which can't have clear fundus examination
  2. Patients with severe systemic diseases who was unable to tolerate the examinations, such as heart failure, respiratory failure, sepsis, severe anemia, kidney disease, history of eye surgery and so on
  3. Patients who was unable to tolerate oxygen treatment, such as severe pulmonary edema, deformity of the respiratory tract, respiratory tract infection, tuberculosis, patients with pregnancy, and so on

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Continuous OxygenContinuous oxygenContinuous oxygen intake and routine drug treatment .
Continuous Oxygen Therapy Combined With Blue Light DeprivationContinuous oxygenContinuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
Blue Light Deprivationblue light-absorbing sunglassesWearing blue light-absorbing sunglasses at daily time and routine drug treatment
Continuous Oxygen Therapy Combined With Blue Light Deprivationblue light-absorbing sunglassesContinuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
Primary Outcome Measures
NameTimeMethod
the percentage of patients preserved 80% of the initial visual acuity at 5 years follow-up.at 5 years follow-up
Secondary Outcome Measures
NameTimeMethod
Retinal vessel oxygen saturationat 5 years follow-up

Retinal Oximetry

ERG b-wave mean valuesat 5 years follow-up
Change of visual fieldat 5 years follow-up

visual field

Fundus changes of fluorescence fundus angiographyat 5 years follow-up
intra-ocular pressureat 1, 2, 3, 4 and 5 years follow-up
blood pressureat 1, 2, 3, 4 and 5 years follow-up
Finger pulse oxygen saturationat 1, 2, 3, 4 and 5 years follow-up

Finger pulse oximetry

the mutant genes of retinitis pigmentosaat admission

gene screening

Trial Locations

Locations (1)

State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath